Abstract
Background The COVID-19 pandemic has resulted in unprecedented challenges to health systems worldwide, including the control of non-COVID-19 diseases. Malaria cases and deaths may increase due to the direct and indirect effects of the pandemic in malaria endemic countries, particularly in sub-Saharan Africa (SSA).
Objectives This scoping review aims to summarize information on public health relevant effects of the COVID-19 pandemic on the malaria situation in SSA.
Methods Review of publications and manuscripts on preprint servers, in peer-reviewed journals and in grey literature documents from December 1, 2019, to June 9, 2021. A structured search was conducted on different databases using predefined eligibility criteria for the selection of articles.
Results A total of 51 papers have been included in the analysis. Modeling papers have predicted a significant increase in malaria cases and malaria deaths in SSA due to the effects of the COVID-19 pandemic. Many papers provided potential explanations for expected COVID-19 effects on the malaria burden; these ranged from relevant diagnostical and clinical aspects, to reduced access to health care services, impaired availability of curative and preventive commodities and medications, and effects on malaria prevention campaigns. Compared to previous years, fewer country reports provided data on the actual number of malaria cases and deaths in 2020, with mixed results. While highly endemic countries reported evidence of decreased malaria cases in health facilities, low endemic countries reported overall higher numbers of malaria cases and deaths in 2020.
Conclusions The findings from this review provide evidence for a significant but diverse impact of the COVID-19 pandemic on malaria in SSA. There is the need to further investigate the public health consequences of the COVID-19 pandemic on the malaria burden.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Anna-Katharina Heuschen acknowledges the support by the Else Kroener-Fresenius-Stiftung within the Heidelberg Graduate School of Global Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
List of abbreviations
- ACT
- artemisinin-based combination therapy
- COVID-19
- coronavirus disease 2019
- CQ
- chloroquine
- DRC
- Democratic Republic of the Congo
- HCW
- health care worker
- IPTp
- intermittent preventive treatment in pregnancy
- IRS
- indoor residual spraying of insecticides
- ITN
- insecticide-treated mosquito net
- LMIC
- low- and middle-income country
- PICo
- problem, interest, context
- PPE
- personal protective equipment
- SARS-CoV-2
- severe acute respiratory coronavirus type 2
- SSA
- sub-Saharan Africa
- WHO
- World Health Organization
